1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER
Anorexia
Mayo Clinicprotein_peptidePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Anorexia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
MEGESTROL ACETATE IMPURITY B Alliance for Clinical Trials in Oncology | Phase 3 | BB |
Docetaxel Alliance for Clinical Trials in Oncology | Phase 3 | B |
Infliximab Alliance for Clinical Trials in Oncology | Phase 3 | B |
Olanzapine Alliance for Clinical Trials in Oncology | Phase 3 | B |
Anamorelin M.D. Anderson Cancer Center | Phase 2/3 | B |
View all 12 →
Same molecule, other indications
1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →